KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...
The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...
The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...
The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback